Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Evaxion Biotech
Biotech
Evaxion stock slips on phase 2 cancer vax data
Out of 16 patients in the phase 2 trial, 12 showed a clinical response to Evaxion’s EVX-01, including four who saw their cancer vanish completely.
Darren Incorvaia
Oct 17, 2025 2:07pm
Merck opts in on Evaxian's preclinical vaccine candidate
Sep 25, 2025 7:00am
Merck bags options on Evaxion's AI-designed vaccine candidates
Sep 26, 2024 7:30am
Biogen CMO Maha Radhakrishnan joins Sofinnova—Chutes & Ladders
Aug 9, 2024 8:30am
Sanofi finds new R&D head—Chutes & Ladders
Sep 1, 2023 9:30am
3 more biotechs look to cull, partner assets
Nov 14, 2022 11:40am
